[Vidarabine-interferon combination in patients with chronic viral hepatitis B of mutant form. Efficiency and tolerability during a pilot study].
Durand
M
M
Bost
F
F
Maynard
M
M
Baud
M
M
Cohard
M
M
Zarski
J P
JP
D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy* / Q000821:virology; D006521:Hepatitis, Chronic / Q000188:drug therapy / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins; D014740:Vidarabine / Q000627:therapeutic use*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014740:Vidarabine
Association vidarabine-interféron chez les patients atteints d'hépatite virale chronique B à forme mutante. Efficacité et tolérance au cours d'une étude pilote.